Topic: The TSRL Preclinical Accelerator: Driving Value from Lead to Clinic
Date: Friday, November 11 Time: 9 to 10 a.m.
Place: B448 Life Science Bldg
Who: Elke Lipka, MBA, PhD, President and Andrew Hertig, MBA, Business Development
About TSRL, Inc.: We are a privately-owned pharmaceutical accelerator based in Ann Arbor, Michigan. We provide academic investigators scientific and business resources and access to non-dilutive capital to advance their lead-stage therapeutic compounds to clinical-readiness. Our core competencies include: pharmacokinetics, formulation development, exploratory toxicology, data and project management, regulatory strategy, grant-writing, and business development. Our programs have received over $15 million in grant support over the past ten years and generated ~$20 million in revenues from out-licenses and acquisitions. Currently, we are focused on the development of anti-infective therapeutics for treating severe and multi-drug resistant infectious diseases.
